David Kim’s Ghost Tree Capital Loves These Healthcare Stocks

Ghost Tree Capital is a healthcare-oriented hedge fund headquartered in New York. It was founded in 2013 by David Kim who is the portfolio manager, Ken Greenberg and Brian Kim (Senior Analysts), and Matt Diaz (trader). Ghost Tree Capital team formerly worked at Richard Schimel‘s Diamondback Capital. David Kim also worked as a portfolio manager at Ken Griffin‘s Citadel Investment Group. With almost 90% of its equity portfolio (valued at approximately $162 million) allocated to the healthcare industry, “the firm’s strategy is focused on driving strong absolute returns, independent of market cycles, based on fundamental primary research and disciplined financial analysis” (Ghost Tree).

Many hedge funds have been filing their 13Fs for the fourth quarter of 2013 lately. In these forms, they disclose most of their long equity positions as of the end of December. Although the portfolio information is a few weeks old, there are still a few ways for investors to use it. In this article, we will briefly look into the equity portfolio of Ken Greenberg and David Kim’s Ghost Tree Capital by the end of the fourth quarter (this was the first time that the fund reported its equity portfolio at the U.S. Securities and Exchange Commission). Although its most valuable holdings are mostly comprised by call and put options at several companies –including Allergan Inc. (NYSE:AGN) and Gilead Sciences Inc. (NASDAQ:GILD), we will focus on its long stock positions.

Gilead Sciences, Inc. (NASDAQ:GILD)

The fund has placed its largest bet on Gilead Sciences Inc. (NASDAQ:GILD), a $128 billion market cap research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. Kim and Greenberg’s fund owned 135,000 shares of the company by Dec. 31st 2013, valued at roughly $11.3 million –which comprises about 6.2% of its equity portfolio. Including ’Put’ and ‘Call’ options, the percentage of its portfolio invested in Gilead raises to roughly 14%. This investment certainly makes sense, especially given the company’s industry leading margins and returns, low debt levels and amazing growth prospects (analysts expect it to deliver average annual EPS growth rates around 36% over the next five years). With a privileged position in the HIV and hepatitis C markets, this stock looks like a safe bet. In addition, it trades at a substantial discount in relation to its peers; at 46 times the company’s earnings, versus an industry average valuation of 75x P/E. Moreover, the stock is already up more than 10% since their purchases. Even further, several other major hedge funds, including Julian Robertson’s Tiger Management, which holds 320,000 shares, up by 26% over Q4, and Lee Munder’s Lee Munder Capital Group, also seem to feel quite bullish on this company. Ghost Tree’s second largest long position is in Bristol-Myers Squibb Co (NYSE:BMY), a biopharmaceutical company with a market cap of $88.9 billion. The fund owns 100,000 shares of the company, valued at $5.4 million. Comprising 3.2% of its portfolio, this holding is the fund’s seventh most valuable one. Despite Ghost Tree’s bullishness, opinion among funds and analysts is quite divided in relation to Bristol-Myers Squibb Co (NYSE:BMY). Some feel encouraged by decent growth projections, a strong portfolio of drugs, a robust pipeline, a wide economic moat –mainly supported by its patent holdings and pipeline, and a 2.69% dividend yield. Amongst them we can find Christopher Medlock’s Partner Fund Management, which holds 7.5 million shares, and Alex Denner’s Sarissa Capital Management. Others, instead, would rather hold on this stock, mainly in account of the company’s below average margins and returns, valuation at 34x P/E (double its industry´s average), high debt levels, and important patent losses that will continue through 2017. In this group of bears, I would like to highlight Jim Simons, who sold out 99% of his stakes in the company during the fourth quarter, amongst several  others who closed out or significantly reduced their positions. The fund’s top 10 list is completed by Biogen Idec Inc (NASDAQ:BIIB) and The Spectranetics Corporation (NASDAQ:SPNC), two healthcare tech companies. Each of these holdings are worth more than $4 million, and comprise, combined, about 5.5% of Ghost Tree’s portfolio. No doubt about it, Ken Greenberg and David Kim’s bets are placed on the healthcare segment. Are their choices good enough for you too? Disclosure: Javier Hasse holds no position in any stocks mentioned. Recommended Reading: David Gallo’s Valinor Management Boosts Stake in dELiA*s Inc (DLIA) Senator Investment Group Reports New Position In Brookdale Senior Living Inc. (BKD) Dan Loeb and Third Point Nominate Three Directors to Sothebys (BID)’s Board

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!